HK Stock Market Move | Pharmaron Beijing's stock has risen by over 7%, Kanglong Shaoxing passes on-site inspection by the US FDA.

Pharmaron Beijing (03759) rose more than 7%, up 7.65% at the time of publication, at HKD 27.86, with a turnover of HKD 574 million. In terms of news, on the evening of September 15, Pharmaron Beijing announced that Kanglong Shaoxing has recently received an Establishment Inspection Report from the US FDA. The inspection report confirms that Kanglong Shaoxing's production facilities have successfully passed the on-site quality inspection by the US FDA. According to the inspection report, Kanglong Shaoxing meets the US drug cGMP quality standards and has been certified by the US FDA. This is the first time that the company's Shaoxing active pharmaceutical ingredient (API) commercial production base has passed the pre-approval inspection by the US FDA, following the April 2025 inspection of the company's API production workshop in Ningbo, China. The announcement stated that this marks the company's quality system is now in line with international standards, enabling it to continuously supply innovative drug APIs for commercial production to the US and global markets. Currently, all 4 API commercial production bases located in China, the UK, and the US have passed the US FDA inspection, providing commercial production solutions for innovative drug APIs tailored to different markets worldwide.